The Children's Hospital of Zhejiang University School of Medicine
With
Ningbo Women & Children's Hospital
Hangzhou Children's Hospital
This multicenter, prospective cohort study is designed to evaluate the effectiveness of a structuralized follow-up model (HEM-SURVIVE) for childhood hematological malignancy survivors in China. Currently, follow-up practices lack a standardized pathway. This study will enroll 400 eligible survivors (aged 1-21 years) and assign them into two cohorts: the structured follow-up mode (utilizing risk stratification, standardized examination packages, MDT clinics, and a dedicated mobile APP) and the conventional follow-up mode. The study aims to accurately assess the burden of late effects (such as cardiovascular events, endocrine disorders, and secondary malignancies) and to determine whether the structured electronic pathway improves patient compliance and early detection rates compared to routine empirical follow-up over a 36-month period.
Age
1–21
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosed with childhood hematological malignancies (ALL, AML, Lymphoma, etc.), Completed primary treatment for ≥12 months.
Age 1-21 years.
Capable of completing follow-up and data collection.
Informed consent signed.
You may not be if
Severe organ failure preventing follow-up.
Major genetic or systemic diseases affecting growth/organ function.
Expected poor compliance or refusal to participate.